BEGIN:VCALENDAR VERSION:2.0 PRODID:IEEE vTools.Events//EN CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:America/Chicago BEGIN:DAYLIGHT DTSTART:20220313T030000 TZOFFSETFROM:-0600 TZOFFSETTO:-0500 RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3 TZNAME:CDT END:DAYLIGHT BEGIN:STANDARD DTSTART:20221106T010000 TZOFFSETFROM:-0500 TZOFFSETTO:-0600 RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11 TZNAME:CST END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTAMP:20220901T200917Z UID:96233340-D3FD-4B62-A232-7D0856C5C99A DTSTART;TZID=America/Chicago:20220518T180000 DTEND;TZID=America/Chicago:20220518T200000 DESCRIPTION:Abstract\n\nTwenty years after the launch of biologic treatment s for patients with rheumatoid arthritis (RA)\, it has become increasingly apparent that only 25% of these patients treated achieve adequate success regardless of the immune target addressed. The solution forced immunologi sts to seek answers in unexpected places and to rely on technology complet ely foreign to them. The immune system is regulated by the brain\, specifi cally the autonomic nervous system (ANS) which modulates fight-or-flight a drenaline and recovery phases. It is measured best by heart rate variabili ty (HRV) - a techniques used to quantify stress in over 50\,000 peer-revie w studies. In addition\, the software\, hardware\, and firmware engineerin g of HRV has been significantly upgraded to enhance its precision.\n\nThis 5-min\, next-generation HRV supports patients with autoimmune disease by applying a cardiovascular platform (ECG) to assess a brain function (ANS) to solve a clinical immunology problem. It is first to predict 52-wk biolo gic outcome in RA with 90% sensitivity and 95.7% specificity in a prospect ive\, double-blind trial. Of equal importance\, optimizing adverse (fight- or-flight predominant) ANS profile increased RA remission from 25% to 79%. The new concept\, called immuno-autonomics\, represents a sea change in c linical care.\n\nSpeaker(s): Dr. Holmen\, \n\nAgenda: \n6:00 PM Family Sty le All-you-can-eat Dinner\n\n7:00 PM Presentation by Andrew J Holman MD\, CEO & Co-founder\, Inmedix\, Inc.\n\n7:45 PM Questions and Discussion\n\n8 :00 PM Adjourn\n\nBldg: Imperial Garden Restaurant\, 2039 Allen Blvd\, Mid dleton\, Wisconsin\, United States\, 53562\, Virtual: https://events.vtool s.ieee.org/m/306745 LOCATION:Bldg: Imperial Garden Restaurant\, 2039 Allen Blvd\, Middleton\, W isconsin\, United States\, 53562\, Virtual: https://events.vtools.ieee.org /m/306745 ORGANIZER:tjkaminski49@gmail.com SEQUENCE:11 SUMMARY:Immuno-Autonomics: A Sea Change in Clinical Care URL;VALUE=URI:https://events.vtools.ieee.org/m/306745 X-ALT-DESC:Description: <br /><p><strong>Abstract</strong></p>\n<p>Twenty y ears after the launch of biologic treatments for patients with rheumatoid arthritis (RA)\, it has become increasingly apparent that only 25% of thes e patients treated achieve adequate success regardless of the immune targe t addressed. &nbsp\;The solution forced immunologists to seek answers in u nexpected places and to rely on technology completely foreign to them. &nb sp\;The immune system is regulated by the brain\, specifically the autonom ic nervous system (ANS) which modulates fight-or-flight adrenaline and rec overy phases. &nbsp\;It is measured best by heart rate variability (HRV) - a techniques used to quantify stress in over 50\,000 peer-review studies. &nbsp\;In addition\, the software\, hardware\, and firmware engineering o f HRV has been significantly upgraded to enhance its precision.&nbsp\;</p> \n<p>This 5-min\, next-generation HRV supports patients with autoimmune di sease by applying a cardiovascular platform (ECG) to assess a brain functi on (ANS) to solve a clinical immunology problem. &nbsp\;It is first to pre dict 52-wk biologic outcome in RA with 90% sensitivity and 95.7% specifici ty in a prospective\, double-blind trial. &nbsp\;Of equal importance\, opt imizing adverse (fight-or-flight predominant) ANS profile increased RA rem ission from 25% to 79%. &nbsp\;The new concept\, called immuno-autonomics\ , represents a sea change in clinical care.</p><br /><br />Agenda: <br />< p>6:00 PM Family Style All-you-can-eat Dinner</p>\n<p>7:00 PM Presentation by Andrew J Holman MD\, CEO &amp\; Co-founder\, Inmedix\, Inc.</p>\n<p><s pan style="font-family: -apple-system\, BlinkMacSystemFont\, 'Segoe UI'\, Roboto\, Oxygen\, Ubuntu\, Cantarell\, 'Open Sans'\, 'Helvetica Neue'\, sa ns-serif\;">7:45 PM Questions and Discussion</span></p>\n<p>8:00 PM Adjour n</p> END:VEVENT END:VCALENDAR